Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.57 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.57 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.57 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26023562 | 1.00 | MAPT (0.68) | MAPTNPC1RAB9ATDP1FFAR1 | |
| SCHEMBL31329294 | 0.91 | ALDH1A1 (0.61) | MAPTNPC1RAB9ATDP1FFAR1 | |
| SCHEMBL490534 | 0.88 | TDP1 (0.70) | MAPTNPC1RAB9ATDP1FFAR1 | |
| SCHEMBL304176 | 0.87 | TDP1 (0.78) | MAPTTDP1FFAR1ALDH1A1L3MBTL1 | |
| SCHEMBL7276062 | 0.86 | FFAR1 (0.74) | TDP1FFAR1LMNAFFAR4ALOX5 | |
| Ammonia Solution, Strong SCHEMBL28588274 | 0.85 | TDP1 (0.75) | MAPTTDP1FFAR1ALDH1A1L3MBTL1 | |
| SCHEMBL28207503 | 0.85 | TDP1 (0.75) | MAPTTDP1FFAR1ALDH1A1L3MBTL1 | |
| SCHEMBL3732372 | 0.85 | ALDH1A1 (0.59) | MAPTNPC1RAB9AFFAR1ALDH1A1 | |
| Bicarbonate SCHEMBL7699565 | 0.85 | TDP1 (0.75) | MAPTTDP1FFAR1ALDH1A1L3MBTL1 | |
| SCHEMBL7059127 | 0.85 | PLAAT3 (0.61) | MAPTNPC1RAB9ATDP1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135100-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | KEZAR LIFE SCIENCES, INC. | 2023-05-04 | — | — | US | disclosed |
| US-10240175-B2 | Compositions and methods for producing benzylisoquinoline alkaloids | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-03-26 | — | — | US | disclosed |
| US-10202626-B2 | — | — | 2019-02-12 | — | — | US | disclosed |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| CN-101267815-B | metallo-beta-lactamase inhibitors | MEIJI SEIKA PHARMA CO LTD | 2013-11-06 | — | — | CN | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| CN-101267815-A | metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA (JP) | 2008-09-17 | — | — | CN | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | MAPT 2687/4885NPC1 2815/4885RAB9A 2261/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | MAPT 2687/4885NPC1 2815/4885RAB9A 2261/4885 |
| US-20230135100-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | PREP, PSMB2, PSME1 | MAPT 1872/4885NPC1 2919/4885RAB9A 2048/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | MAPT 2972/4885NPC1 2708/4885RAB9A 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.